Notably, patients with PD-L1 CPS <1 also demonstrated significant benefits, with an ORR of 35.7% and a median PFS of 12.8 months, indicating cadonilimab could also provide encouraging anti-tumor activity even in PD-L1 CPS <1 subgroup. The gene discussed is CD274; the disease is neoplasm.